• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersBrainstorm Health

A Federal Panel Says All Adults Should Be Screened for Drug Addiction: Brainstorm Health

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
August 13, 2019, 6:20 PM ET

Good afternoon, readers.

The U.S. Preventive Services Task Force—somewhat more simply known as the USPSTF—is a pretty influential part of the Department of the Health and Human Services (HHS).

The independent panel has the power to advise on exactly what medical services are critical to provide to the general public, or which services doctors should generally be expected to give—and, under the Affordable Care Act, the group’s recommendations could potentially become services which must be covered by insurance for free or minimal out-of-pocket payments.

Well, the USPSTF has a new recommendation for doctors across the country: Screen every adult patient for illicit drug use as part of a crackdown on the opioid crisis.

Drug overdose deaths dropped for the first time since 1990 last year, according to government data. But the opioid overdose epidemic is far from over. And even this latest screening recommendation doesn’t encompass all potential patients, including teenagers.

Read on for the day’s news.

Sy Mukherjee, @the_sy_guy, [email protected]

DIGITAL HEALTH

New Hampshire expands telemedicine access. New Hampshire Gov. Chris Sununu this week signed a bill that could expand telemedicine's availability in the Granite State. One of the biggest road bumps to telemedicine access—across the country—has been restrictions on whether certain public programs such as Medicaid can cover them. The New Hampshire bill would add primary care workers and pediatricians to the list of providers who can bill the state's Medicaid program for telehealth consults, according to New Hampshire Public Radio. (Nhpr)

INDICATIONS

Eli Lilly stock rises on psoriasis drug data. Shares of Eli Lilly rose nearly 2% in Tuesday trading after new clinical data showed its psoriasis drug could be superior to a Johnson & Johnson rival—and also potentially pose a threat to a recently-approved treatment from AbbVie, which absolutely dominates the psoriasis (a common, itchy skin condition) space. (BioPharma Dive)

THE BIG PICTURE

Britain's Brexit problem.  We've brought this up a few times—but, with the clock ticking on Brexit, it feels worth mentioning again: A "No-Deal" Brexit could disrupt the U.K. Patients' access to medicines in a major way. In fact, the disruptions could ripple well past Britain, as Reuters reports. (Reuters)

REQUIRED READING

What the Heck Is a Negative Mortgage Rate?By Erik Sherman

Verizon to Sell Tumblr to Wordpress Owners, Reports Say, by David Z. Morris

Why Is Job Hunting (Still) So Slow?By Anne Fisher

Find past coverage. Sign up for other Coins2Day newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.